Answers are grounded in this paper and cite their sources.
Niclosamide has previously been shown to have immunomodulatory properties, and several mechanisms have been proposed. We previously showed that niclosamide inhibits immune cell response to lipopolysaccharide by modulating inflammasome activity. Our work also demonstrated that small‐molecule drugs can restrict GLUT‐mediated substrate accumulation and modulate IL‐1β secretion. Since glucose accumulation and glycolysis are crucial in immune cells, we studied niclosamide’s effects on glucose metabolism and responses in THP‐1 cells. We found that 24‐hour niclosamide exposure increased glucose accumulation and lactate secretion while reducing mitochondrial respiratory capacity, glyceraldehyde 3‐phosphate dehydrogenase (GAPDH) activity, and hexokinase activity. Higher niclosamide concentrations resulted in even lower GAPDH and hexokinase activity, regardless of preactivation. Cytokine and chemokine secretion, including IL‐1β, depended on the activation status of THP‐1 cells, showing context‐dependent immunomodulation. The data presented here support the immunomodulatory potential of niclosamide and provide further insight into its effects on cellular metabolism and cytokine secretion that may help explain conflicting reports on its activity in the literature.
No takes yet. Share an insight, caveat, or question.
Wingrave et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: